Targeted therapy in eosinophilic chronic obstructive pulmonary disease

Mathieu Fieldes (1, 2) , Chloé Bourguignon (1, 2, 3) , Said Assou (1, 2) , Amel Nasri (1, 2) , Aurélie Fort (4, 2) , Isabelle Vachier (5, 2) , John de Vos (1, 2) , Engi Ahmed (5, 2) , Arnaud Bourdin (4, 2)

1 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)
2 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
3 IDESP - Institut Desbrest de santé publique
4 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
5 INSERM - Institut National de la Santé et de la Recherche Médicale

Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8 + T-cells. Asthma is a heterogeneous chronic inflammatory airway disease. The most studied subtype is type 2 (T2) high eosinophilic asthma, for which there are an increasing number of biologic agents developed. However, both asthma and COPD are complex and share common pathophysiological mechanisms. They are known as overlapping syndromes as approximately 40% of patients with COPD present an eosinophilic airway inflammation. Several studies suggest a putative role of eosinophilia in lung function decline and COPD exacerbation. Recently, pharmacological agents targeting eosinophilic traits in uncontrolled eosinophilic asthma, especially monoclonal antibodies directed against interleukins (IL-5, IL-4, IL-13) or their receptors, have shown promising results. This review examines data on the rationale for such biological agents and assesses efficacy in T2-endotype COPD patients. @ERSpublications Patients with severe COPD and eosinophilic inflammation experience uncontrolled symptoms despite optimal pharmaceutical treatment. The development of new biomarkers is needed for better phenotyping of patients to propose innovative targeted therapy.

Domaines: Pneumologie et système respiratoire; Immunothérapie

Mathieu Fieldes, Chloé Bourguignon, Said Assou, Amel Nasri, Aurélie Fort, et al.. Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Research, 2021, 7 (2), pp.00437-2020. ⟨10.1183/23120541.00437-2020⟩. ⟨hal-03200459⟩